Loading organizations...
GH Research is a clinical-stage biopharmaceutical company based in Dublin, Ireland, that develops novel mebufotenin therapies for treatment-resistant depression and other psychiatric disorders. The organization focuses on advancing its lead product candidate, GH001, which is currently undergoing randomized, double-blind, placebo-controlled Phase 2b clinical trials. Additionally, the pipeline includes proprietary injectable and intranasal formulations, designated as GH002 and GH003, designed to target patients who have limited options with existing therapies. Following private Series A and Series B financing rounds, the enterprise completed an upsized initial public offering on the NASDAQ in June 2021, generating approximately $167.6 million in net proceeds to fund ongoing clinical development. The corporate leadership and board of directors include notable industry figures such as Vice Chairman Michael Forer, Dermot Hanley, and Duncan Moore. GH Research was founded in 2018 by Florian Schönharting and Magnus Halle.
GH Research has raised $125.0M across 1 funding round.
GH Research has raised $125.0M in total across 1 funding round.
GH Research has raised $125.0M in total across 1 funding round.
GH Research's investors include RA Capital Management, RTW Investments, Acuta Capital Partners, Boxer Capital, BVF Partners, Cormorant Asset Management, Deerfield Management, Logos Capital, Surveyor Capital, Venrock, Verition Fund Management.
GH Research has raised $125.0M across 1 funding round. Most recently, it raised $125.0M Series B in April 2021.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Apr 12, 2021 | $125M Series B | RA Capital Management, RTW Investments | Acuta Capital Partners, Boxer Capital, BVF Partners, Cormorant Asset Management, Deerfield Management, Logos Capital, Surveyor Capital, Venrock, Verition Fund Management | Announced |
